Cogent Biosciences Announces $150 Million Public Offering

Strategic Insights -

Cogent Biosciences, a biotechnology company focused on developing precision therapies for genetically defined diseases, has commenced an underwritten public offering of $150 million of its shares of common stock. The company intends to use the net proceeds from the offering for continued development, regulatory and commercial preparation activities relating to bezuclastinib and other product candidates, as well as for working capital and general corporate purposes. This announcement marks a significant milestone for the company, with ongoing Phase 1 studies for its novel internally discovered FGFR2 inhibitor and a portfolio of novel targeted therapies in development.

Key Takeaways:

  • Cogent Biosciences has initiated an underwritten public offering of $150 million of its shares of common stock, with the option to purchase up to an additional $22.5 million.
  • The net proceeds from the offering will be used for continued development, regulatory and commercial preparation activities for bezuclastinib and other product candidates.
  • Cogent Biosciences has ongoing Phase 1 studies for its novel internally discovered FGFR2 inhibitor and a portfolio of novel targeted therapies targeting mutations in ErbB2, PI3Kα and KRAS.
  • The company operates with dual headquarters in Waltham, MA and Boulder, CO.
  • Cogent Biosciences has a strong pipeline of precision therapies for genetically defined diseases, with a focus on developing effective treatments for severe conditions.

Statistics:

  • The proposed underwritten public offering consists of $150 million in shares of common stock, with an option to purchase up to an additional $22.5 million.
  • The Securities and Exchange Commission (SEC) has approved Cogent Biosciences' automatic shelf registration statement on Form S-3ASR (File No. 333-269707), which became effective on February 10, 2023, upon filing.
  • The company is developing a total of three novel therapy candidates, including bezuclastinib, FGFR2 inhibitor, and targeted therapies targeting ErbB2, PI3Kα and KRAS mutations.

Sources:

  • GLOBE NEWSWIRE, "Cogent Biosciences, Inc. Announces Underwritten Public Offering" (July 08, 2025)
  • Cogent Biosciences' Automatic Shelf Registration Statement on Form S-3ASR (File No. 333-269707), filed with the SEC on February 10, 2023, and automatically became effective upon filing.